Press Releases

ERT Recognized for Patient-Focused Technological Development in Clinical Trials

Sep 18, 2016, 18:48 PM by Michael Croft
PHILADELPHIA, PA, UNITED STATES - Sep 19, 2016 - ERT, a leading provider of high-quality patient data collection solutions for use in clinical drug development, today announced that it has been named a finalist for the 2016 Scrip Award, Best Patient-Focused Technological Development in Clinical Trials, for its innovative electrocardiogram (ECG) / electronic Clinical Outcome Assessment (eCOA) integration
Named finalist for 2016 Scrip Awards for ECG/eCOA data integration

PHILADELPHIA, PA, UNITED STATES - Sep 19, 2016 - ERT, a leading provider of high-quality patient data collection solutions for use in clinical drug development, today announced that it has been named a finalist for the 2016 Scrip Award, Best Patient-Focused Technological Development in Clinical Trials, for its innovative electrocardiogram (ECG) / electronic Clinical Outcome Assessment (eCOA) integration.                                                                                                                                                    

ERT’s integrated wireless ECG/eCOA tablet solution enables clinical researchers to collect vital, objective safety and efficacy endpoint data, resulting in a more comprehensive view into patient health and well-being. By integrating the collection of critical endpoints, researchers can spend more time managing patients and actioning results to improve the quality and efficiency of clinical trials. 

A representative of the Scrip Award program noted, “ERT’s placement on the 2016 shortlist is representative of the full range of industry activities from big pharma, biotech companies and CROs being recognized for novel deals,  new drug launches and technological breakthroughs in clinical trials.”

“We are pleased to be recognized for our commitment to developing innovative solutions that enable accurate and real-time collection of critical study endpoints that researchers can have confidence in as they develop new medical products,” said Amy Furlong, Executive Vice President and Product Line Executive, Cardiac Safety at ERT.

For additional information, visit https://www.ert.com/ecg-ecoa-tablet/.

 

About ERT

ERT is a leading provider of high-quality patient data collection solutions for use in clinical drug development. ERT delivers a combination of technology, services and clinical consulting that increase the accuracy and reliability of patient data and improve the efficiency of the clinical development process. ERT delivers widely deployed solutions in centralized Cardiac Safety, Respiratory, and electronic Clinical Outcome Assessments (eCOA) - which includes patient-, clinician-, observer- and performance-reported outcomes - and cloud-based analytics and performance metrics. By efficiently integrating these solutions through a system built upon a scientific and regulatory foundation, ERT collects, analyzes and delivers safety and efficacy data critical to the approval, labeling and reimbursement of pharmaceutical products. For more information, see www.ert.com. Join ERT on LinkedIn, Twitter, YouTube and  Facebook.